Quercus Molecular Design
Quercus Molecular Design (QMD) is dedicated to developing new therapeutic agents for infectious diseases and cancer by leveraging discoveries in molecular virology, drug resistance, and medicinal chemistry. Founded in 2015, QMD focuses on multi-targeting small molecule inhibitors and has a platform originally developed for human herpesviruses, now expanded to include SARS-CoV-2. The company is supported by federal research funding and collaborates with academic institutions like UConn and Yale, aiming to translate scientific discoveries into innovative treatments.
Industries
Nr. of Employees
small (1-50)
Products
Multi-target small-molecule discovery platform
A discovery approach and platform that designs and screens small molecules to simultaneously engage multiple essential protein targets to improve potency and reduce resistance.
Novel therapeutics programs for herpesviruses and CMV
Project initiatives focused on discovery and development of novel small-molecule therapeutics targeting herpes simplex viruses and cytomegalovirus.
Multi-target small-molecule discovery platform
A discovery approach and platform that designs and screens small molecules to simultaneously engage multiple essential protein targets to improve potency and reduce resistance.
Novel therapeutics programs for herpesviruses and CMV
Project initiatives focused on discovery and development of novel small-molecule therapeutics targeting herpes simplex viruses and cytomegalovirus.
Services
Design and synthesis of small-molecule series, scalable route development, and impurity/metabolite characterization to support lead optimization and preclinical material supply.
Development of biochemical and cell-based assays and execution of HTS campaigns to identify and prioritize chemical matter.
Design and oversight of ADME/PK/PD studies and in vivo efficacy experiments to evaluate lead candidates.
Management of multidisciplinary translational research projects to move academic discoveries toward commercialization.
Design and synthesis of small-molecule series, scalable route development, and impurity/metabolite characterization to support lead optimization and preclinical material supply.
Development of biochemical and cell-based assays and execution of HTS campaigns to identify and prioritize chemical matter.
Design and oversight of ADME/PK/PD studies and in vivo efficacy experiments to evaluate lead candidates.
Management of multidisciplinary translational research projects to move academic discoveries toward commercialization.
Expertise Areas
- Small-molecule drug discovery
- Antiviral therapeutics
- Medicinal chemistry and lead optimization
- Preclinical development and animal models
Key Technologies
- Structure-based drug design
- High-throughput screening (HTS)
- Synthetic organic chemistry
- ADME/PK/PD studies and modeling